Abstract
The purpose of this work was to formulate prolonged release matrix tablets with water soluble opioid drug (API) using different types of hydroxypropylmethyl cellulose (Methocel) as controlled release polymers. Methocel K100M was incorporated as intra-granular polymer (sample 1) along with Methocel K4M (sample 2) or Methocel K15M (sample 3) as extra-granular polymers. The final blends and tablets prepared by wet granulation process were fully characterized. Results showed that the polymer used extra-granularly significantly affects the tablet properties. By incorporation of Methocel extra granularly (samples 2 and 3), the hardness and tensile strength of the tablets increased and the total tablet porosity decreased. Sample 1, containing only Methocel K100M (intra granularly) has the lowest index of swelling and the fastest release of API probably due to the cross-linking of the polymer chains during the process of wet granulation. Also, the type of Methocel used extra-granularly (with different viscosity grade) was found to significantly affect the swelling ratio of the designed matrix systems and the drug release behavior. Sample 2 containing Methocel K4M extra-granularly has a lower index of swelling and faster release of API compared to sample 3. Considering the release mechanism, release data showed best fitting to the heuristic model proposed by Korsmeyer-Peppas. Two additional approaches were used for mathematical modeling of the release data in order to make them directly applicable for our experimental results. Keywords: matrix tablet, water soluble opioid drug, prolonged release, HPMC (Methocel)
Highlights
The recognition and treatment of pain have become a major focus of health-care professionals
Glavas Dodov administration, especially for agents with a short elimination half-life was recognized as inconvenient for the patients with chronic pain (Smith, 2012)
These problems could be overcome by using oral modifiedrelease products with prolonged drug release as an efficient technological strategy for management of moderate-to-severe chronic pain
Summary
The recognition and treatment of pain have become a major focus of health-care professionals. Oral opioids have become the drugs of choice for the treatment of. Glavas Dodov administration, especially for agents with a short elimination half-life was recognized as inconvenient for the patients with chronic pain (Smith, 2012). These problems could be overcome by using oral modifiedrelease products with prolonged drug release as an efficient technological strategy for management of moderate-to-severe chronic pain
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
